RNA blood test shows promise for earlier Alzheimer's detection

A blood test that reads the molecular whispers traveling from your brain might soon catch Alzheimer's disease before you notice anything is wrong. Researchers have identified RNA signatures circulating in the bloodstream that appear to signal the disease's presence earlier than the protein markers doctors currently rely on—a finding that could reshape how millions of people at risk get screened and monitored.

The work centers on tiny structures called extracellular vesicles and particles, or EVPs. These are membrane-bound packages released constantly by cells throughout the body, some small enough to cross the barrier between blood and brain, carrying molecular cargo from the brain into the general circulation. By analyzing blood and brain tissue samples from people with Alzheimer's and healthy controls, researchers isolated different types of these particles and examined what RNA they contained. What emerged was a distinct pattern: certain RNA sequences appeared consistently in the blood of Alzheimer's patients but not in others.

Among their discoveries was a newly identified nanoparticle they named a SECmere—a particle smaller than 50 nanometers, enriched with markers from brain cells. These SECmeres appear to act as a kind of biological courier, carrying brain-specific RNA signals into the bloodstream where a simple blood draw can capture them. Navneet Dogra, an assistant professor at the Icahn School of Medicine at Mount Sinai and a lead researcher on the work, explained that these particles are significant precisely because they originate from brain cells and carry RNA that reflects what is happening inside the brain. The findings were published in Nature Communications.

Why does this matter? Current Alzheimer's diagnosis remains frustratingly difficult, especially in early stages when symptoms overlap with normal aging or other conditions. Doctors have traditionally relied on expensive brain imaging scans or invasive lumbar punctures that sample cerebrospinal fluid—procedures that are costly, uncomfortable, and not practical for routine screening. In 2025, the FDA approved the first protein-based blood test for Alzheimer's, a significant step forward. But the new research suggests RNA may detect disease changes even earlier, before proteins accumulate or brain damage becomes visible on scans. That earlier window could mean the difference between catching the disease when intervention is still possible and discovering it after irreversible decline has begun.

The global stakes are enormous. Alzheimer's is the most common form of dementia, currently affecting more than 55 million people worldwide. Projections suggest that number will climb to 150 million by 2050. Early detection is becoming critical because it allows doctors to monitor at-risk individuals more closely, select better candidates for clinical trials, and potentially start treatment before the disease progresses too far. A blood test that could identify these changes simply and affordably would be transformative for public health.

Dogra and his team are now planning longitudinal studies to track when these RNA biomarkers first appear in the disease process and how they evolve over time. They are also working toward developing a straightforward PCR assay—a standard molecular test—that could measure RNA changes in blood samples. The goal is to create something practical enough for routine clinical use, accessible enough for widespread screening, and reliable enough to guide treatment decisions. The research is still early, and larger clinical studies will be needed to confirm that RNA biomarkers can do what the initial findings suggest. But the direction is clear: the future of Alzheimer's detection may depend not on what we can see in the brain, but on what we can read in the blood.